Roundup: Novavax, Micros, Sprint

From staff and wire reports

*Vaccine maker Novavax said it opened its first plant that will be used to manufacture vaccines for infectious diseases in the United States. The $5 million, 5,000-square-foot facility at the company's headquarters in Rockville will focus on producing flu vaccine for Novavax's clinical programs, with planned annual capacity of 10 million doses.
Although the company does not currently have any vaccines on the market, its lead candidate is for pandemic flu, currently in mid-stage testing. Its other candidates are for pandemic flu, shingles and HIV.

*Shares of Micros Systems of Columbia fell about 16 percent after it said 2008 profit probably won't meet analysts' expectations.

*Sprint Nextel, formerly of Reston, said it has named Robert H. Brust, 64, as chief financial officer, effective immediately. Brust served as executive vice president and CFO of Eastman Kodak from 2001 to 2007 and was previously CFO of Unisys. He replaces Paul Saleh, who left Sprint in January along with two other top executives.
William G. Arendt, Sprint's controller, had served as acting CFO.
Separately, Standard & Poor's cut Sprint's credit rating to junk.

By Terri Rupar  |  May 1, 2008; 3:42 PM ET  | Category:  Roundup
Previous: Earnings: Dominion, United Therapeutics, Vanda | Next: Earnings: ComScore, Liquidity Services, Sourcefire


Please email us to report offensive comments.

The comments to this entry are closed.

RSS Feed
Subscribe to The Post

© 2010 The Washington Post Company